source
- Lilly’s EloraTZP combo shows superior weight loss and glucose control, moves to Phase 3Eli Lilly reported that its experimental combination, EloraTZP, which pairs an amylin agonist with the approved obesity drug Zepbound, met all primary and secondary goals in a mid‑stage study of ad…
- Eli Lilly’s Zepbound plus amylin candidate shows 23% weight loss in phase 2 trial, but many patients stopped treatmentEli Lilly tested a combination of its GLP‑1 obesity drug Zepbound with the amylin‑targeting candidate eloralintide in a mid‑stage study of people with obesity and type 2 diabetes. After 48 weeks,…